Floatz logo

Ibrutinib

CD79A Gene Mutation

Chinese Academy of Medical SciencesSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the CD79A Gene Mutation cohort.

Asset / SponsorPhaseRating
Epirubicin
Henan Cancer Hospital
Phase 2CCC
PREDNISONE TABLETS
Henan Cancer Hospital
Phase 2CCC
(+)-VINCRISTINE
Henan Cancer Hospital
Phase 2CCC
Zanubrutinib
Henan Cancer Hospital
Phase 2CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Chinese Academy of Medical Sciences
Phase 2CCC
Cyclophosphamide
Henan Cancer Hospital
Phase 2CCC

Same molecule, other indications

Ibrutinib is also rated in:

lymphoid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
70 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →